Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Novelstem International Corp (PK:NSTM)

Business Focus: Bio Therapeutic Drugs

Get the company report for the most recent outlook updated daily

Insider Chart - Past 6 Months

Insider Filings

Latest 10 SEC Form 4 filings for NSTM*US within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Jul 13, 2023 16:03 ET
Arbitration Confirms NovelStem Joint Venture's Rights to Exploit 'Tom Clancy's Net Force' Franchise Globally via Film, TV, Online, Streaming, Gaming and Merchandising
Boca Raton, Florida--(Newsfile Corp. - July 13, 2023) - NovelStem International Corp. (OTC Pink: NSTM) announced today that an Arbitrator has confirmed Netco Partners' rights to broadly license the "Net Force" concept with the Tom Clancy name as a possessory credit (Tom Clancy's Net Force) in TV, streaming, online, films and video games, including all ancillary rights. The Net Force concept is considered to have pioneered storytelling in the thrilling, fast-paced worlds of digital crimes, espionage and crypto. Netco Partners is a 50/50 joint venture between NovelStem International Corp. ("NovelStem") and C.P. Group, Inc.
Read full article
Mar 31, 2023 14:54 ET
NovelStem, Focused on a Patented Genetic Platform Technology for Anti-Cancer Therapies, Reports 2022 Results on Form 10-K
Boca Raton, Florida--(Newsfile Corp. - March 31, 2023) - NovelStem International Corp. (OTC Pink: NSTM), a development-stage company focused on the stem cell-based technology platform developed by Israel-based NewStem Ltd., today filed its Form 10-K for the year ended December 31, 2022. NovelStem owns a 30.58% equity interest in NewStem Ltd.
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
0.15
--
--
Price to Sales - TTM
156.27
5.91
3.32
Price to Book - most recent quarter
--
2.42
2.21
Price to Cash Flow per share - TTM
--
17.80
14.62
Price to Free Cash Flow per share - TTM
--
17.54
24.76
See all valuations

Business Summary

Sector:  Healthcare Industry:  Biotechnology & Medical Research

NovelStem International Corp. is a development-stage biotechnology holding company focused on stem cell-based technology. The Company's primary assets are NewStem Ltd (NewStem) and NetCo Partners (NetCo). NewStem is principally focused on utilizing proprietary human Pluripotent Stem Cells (hPSCs) and Haploid human Pluripotent Stem Cells (HhPSCs) in the development of diagnostic and therapeutic products in oncology. NewStem performs genome-wide genetic screening to identify synthetic lethal interactions with common cancer-related mutations. NewStem's bio-platform is based on haploid human embryonic stem cell technology for genome-wide screenings. Its NewStem Software Diagnostic Device (NSDD) is a bioinformatics-based software medical device platform that provides oncologists with information regarding the presence of mutations in tumors, which may confer patient resistance to certain anti-cancer drugs.

See business summary

 

Twitter

Search (past week) for $NSTM

  • No tweets found